Table 5.
Chemoattractant GPCRs associated with tumor neovascularization.
| Receptors | Tumors | |
|---|---|---|
| Vasculogenesis | FPR1 | Glioma [160] |
| FPR2 | Ovarian cancer [123] | |
| CCR2 | Hepatocellular carcinoma [460] | |
| CCR5 | Hepatocellular carcinoma [460] | |
| CCR6 | Hepatocellular carcinoma [461] | |
| CXCR2 | Pancreatic cancer [462] | |
| CXCR4 | Breast cancer [320], melanoma [463] | |
|
| ||
| Angiogenesis | FPR1 | Glioma [161, 162, 316] |
| C5aR | Epithelial ovarian cancer [17] | |
| CCR1 | Hepatocellular carcinoma [464], lymphoma [465], multiple myeloma [466] | |
| CCR2 | Breast cancer [22, 467, 468], esophageal cancer [469], gastric cancer [381], melanoma [470] | |
| CCR4 | Breast cancer [194] | |
| CCR5 | Multiple myeloma [466], renal cell carcinoma [326] | |
| CCR10 | Ovarian cancer [35] | |
| CXCR1 | Prostate cancer [471], renal cell carcinoma [37] | |
| CXCR2 | Cervical cancer [472], colorectal cancer [258, 259], glioblastoma [473], lung adenocarcinoma [267, 474, 475], melanoma [418, 476], ovarian cancer [268], pancreatic cancer [269, 477–479], prostate cancer [480], renal cell carcinoma [37, 481] | |
| CXCR1/2 | Glioblastoma [482], melanoma [251, 253], multiple myeloma [483], ovarian cancer [484], pancreatic cancer [485], prostate cancer [254, 451, 486], renal cell carcinoma [37] | |
| CXCR4 | Breast cancer [487], colorectal cancer [488, 489], gastric cancer [490], glioblastoma [491–493], hepatocellular carcinoma [494], ovarian cancer [495], pancreatic cancer [269, 496], prostate cancer [497], squamous cell carcinoma [398] | |
| CXCR6 | Hepatocellular carcinoma [3], prostate cancer [295] | |
| CXCR7 | Bladder cancer [498], breast cancer [297], breast and lung cancer [499], colorectal cancer [488], hepatocellular carcinoma [301], prostate cancer [500], renal cell carcinoma [501] | |
| CX3CR1 | Breast cancer [96], colorectal cancer [149], melanoma [502] | |